Update re AbC-19 Rapid Test

RNS Number : 8379M
Omega Diagnostics Group PLC
26 January 2021
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Update re AbC-19TM Rapid Test &

Launch of COVID-19 antibody laboratory-based testing service

 

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes today's update from Abingdon Health plc (AIM: ABDX) ("Abingdon Health") regarding the AbC-19TM Rapid Test, confirming their expectations for future supply arrangements with the Department of Health and Social Care, the ongoing efforts to obtain regulatory approvals in a total of 27 geographies, and the ongoing work to build data the set(s) around the use-case for the AbC-19TM Rapid Test alongside vaccines.

 

In addition, Omega will today announce the laun ch of its COVID-19 antibody lab-based testing service in Littleport, Cambridgeshire (see separate RNS Reach for details), using the Mologic ELISA1 antibody test. This service will be offered to commercial occupational health partners, clinics and health care professionals in the UK.

 

Colin King, CEO of Omega Diagnostics, said: "We welcome the update from Abingdon Health this morning and look forward to being able to update investors on the potential to open up significant commercial opportunities outside of the UK in due course."

 

 

1 ELISA ( Enzyme Linked Immuno-Sorbent Assay)

 

Contacts: 

 

Omega Diagnostics Group PLC 

Tel: 01259 763 030

Bill Rhodes, Interim Non-Executive Chairman

Colin King, Chief Executive 

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director




finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)


Alice Lane (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCZZGZMMKFGMZZ
UK 100

Latest directors dealings